Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

Home
/
update
/
details

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

NextEdge Admin

31 Oct 2024

2 min 0 sec

non-small cell lung cancer,AstraZeneca,Daiichi Sankyo

The first patients have been dosed in three global phase 3 trials assessing datopotamab deruxtecan (Dato-DXd)-based therapies for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). Datopotamab deruxtecan, a TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo, is co-developed with AstraZeneca.

The TROPION-Lung10 trial examines datopotamab deruxtecan combined with rilvegostomig—AstraZeneca’s PD-1/TIGIT bispecific antibody—or rilvegostomig alone, versus pembrolizumab in patients with high PD-L1 expression (≥50%) without actionable mutations. TROPION-Lung14 evaluates the combination of datopotamab deruxtecan and osimertinib, AstraZeneca's EGFR tyrosine kinase inhibitor, against osimertinib alone in untreated, EGFR-mutated nonsquamous NSCLC. TROPION-Lung15 assesses datopotamab deruxtecan, with or without osimertinib, compared to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC that progressed after osimertinib.

“These trials are essential to understanding datopotamab deruxtecan’s potential in treating different lines and types of lung cancer,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development at Daiichi Sankyo. “Our expanding TROPION program underscores our commitment to lung cancer research.”

AstraZeneca’s Chief Medical Officer, Cristian Massacesi, MD, added, “Combining an ADC with targeted or bispecific immunotherapies may produce more durable tumor responses. These phase 3 trials reflect our pursuit of innovative combination therapies within our oncology pipeline and for TROP2-directed ADCs across NSCLC settings.”